Tan Wei-Qiang, Liu Qing, Cen Ming-Jun, Leong Ian I, Pan Zhao-Quan, Liao Mu-Xi, Zhuang Li-Xing
Guangxi University of Chinese Medicine, Nanning, China.
Guangzhou University of Chinese Medicine, Guangzhou, China.
Front Neurol. 2024 Jul 31;15:1328911. doi: 10.3389/fneur.2024.1328911. eCollection 2024.
To systematically evaluate the efficacy of hyperbaric oxygen therapy (HBOT) as an adjunct therapy for treating sleep disorders in patients with Parkinson's disease (PD).
We conducted comprehensive searches in eight databases from inception through September 2023, including PubMed, Cochrane Library, Embase, Web of Science, SinoMed, China National Knowledge Infrastructure (CNKI), China Science and Technology Periodical Database (VIP), and Wanfang Database. The objective was to identify randomized controlled trials (RCTs) evaluating HBOT's effectiveness in alleviating sleep disorder symptoms in PD patients as an adjunct therapy. Literature screening and data extraction were independently executed by the authors. Meta-analyses were performed using Review Manager 5.3 software, and publication bias and sensitivity analyses were assessed using Stata 17.0 software.
Seven RCTs involving 461 participants were included. The findings revealed that the addition of HBOT significantly enhanced sleep efficiency (MD = 15.26, 95% CI [10.89, 19.63], < 0.00001), increased time in bed (MD = 69.65, 95% CI [43.01, 96.30], < 0.00001), total sleep time (MD = 75.87, 95% CI [25.42, 126.31], = 0.003), slow-wave sleep (SWS) time (MD = 6.14, 95% CI [3.95, 8.34], < 0.00001), and rapid eye movement sleep (REM) time (MD = 4.07, 95% CI [2.05, 6.08], < 0.0001), and reduced awakening frequency (MD = -11.55, 95% CI [-15.42, -7.68], < 0.00001) and sleep latency (MD = -6.60, 95% CI [-9.43, -3.89], < 0.00001). Additionally, significant improvements were observed in the Pittsburgh Sleep Quality Index (PSQI) (MD = -2.52, 95% CI [-2.85, -2.18], < 0.00001), Epworth Sleepiness Scale (ESS) (MD = -2.90, 95% CI [-3.34, -2.47], < 0.00001), Unified Parkinson's Disease Rating Scale Part III (UPDRS III) (MD = -1.32, 95% CI [-2.16, -0.47], = 0.002), and Hoehn and Yahr grading (H-Y grading) (MD = -0.15, 95% CI [-0.28, -0.01], = 0.03).
The current meta-analysis supports the efficacy of HBOT as an adjunct therapy in managing sleep disorders in PD patients. It is recommended for PD patients experiencing sleep disturbances.https://www.crd.york.ac.uk/, identifier: CRD42023462201.
系统评价高压氧治疗（HBOT）作为辅助治疗帕金森病（PD）患者睡眠障碍的疗效。
我们从数据库建库至2023年9月在八个数据库中进行了全面检索，包括PubMed、Cochrane图书馆、Embase、Web of Science、中国生物医学文献数据库、中国知网、维普资讯网和万方数据库。目的是识别评估HBOT作为辅助治疗缓解PD患者睡眠障碍症状有效性的随机对照试验（RCT）。文献筛选和数据提取由作者独立完成。使用Review Manager 5.3软件进行荟萃分析，并使用Stata 17.0软件评估发表偏倚和敏感性分析。
纳入了7项涉及461名参与者的RCT。结果显示，添加HBOT显著提高了睡眠效率（MD = 15.26，95%CI[10.89，19.63]，P < 0.00001），增加了卧床时间（MD = 69.65，95%CI[43.01，96.30]，P < 0.00001）、总睡眠时间（MD = 75.87，95%CI[25.42，126.31]，P = 0.003）、慢波睡眠（SWS）时间（MD = 6.14，95%CI[3.95，8.34]，P < 0.00001）和快速眼动睡眠（REM）时间（MD = 4.07，95%CI[2.05，6.08]，P < 0.0001），并减少了觉醒频率（MD = -11.55，95%CI[-15.42，-7.68]，P < 0.00001）和睡眠潜伏期（MD = -6.60，95%CI[-9.43，-3.89]，P < 0.00001）。此外，匹兹堡睡眠质量指数（PSQI）（MD = -2.52，95%CI[-2.85，-2.18]，P < 0.00001）、爱泼沃斯思睡量表（ESS）（MD = -2.90，95%CI[-3.34，-2.47]，P < 0.00001）、帕金森病统一评分量表第三部分（UPDRS III）（MD = -1.32，95%CI[-2.16，-0.47]，P = 0.002）和霍恩和雅尔分级（H-Y分级）（MD = -0.15，95%CI[-0.28，-0.01]，P = 0.03）也有显著改善。
当前的荟萃分析支持HBOT作为辅助治疗管理PD患者睡眠障碍的疗效。建议用于有睡眠障碍的PD患者。https://www.crd.york.ac.uk/，标识符：CRD42023462201。
